R-Pharm is a Russian private hi-tech pharmaceutical company founded in 2001, employs over 3500 highly qualified specialists, has over 60 branches. Turnover reached over $ 1,5 billion in 2013. R-Pharm operates in Russia and CIS, USA, Germany, Japan and India. The company is involved in R&D, manufacturing, marketing, sales and distribution of innovative pharmaceutical products from a broad number of therapeutic areas in specialty/hospital care. The company has operational GMP compliant manufacturing sites at Yaroslavl, Kostroma region and Germany and Novosibirsk/ R-Pharm is building a modern facility for the synthesis of active pharmaceutical ingredients in Rostov – Pharmoslavl. It is expected that the first phase of Pharmoslavl site will be put into operation in the end of 2016. The new facility will comply with the highest requirements of environmental and occupational safety and health standards for the workplace.
Over the time of operation of its manufacturing facilities the company has successfully passed audits and evaluation visits from the largest Global Pharma companies, such as Abbvie, Amgen, Astellas, AstraZeneca, BMS, Boryung, Dr.Reddy’s, Eli Lilly, Ferring, Glaxo Smith Kline, Johnson& Johnson, Mallinckrodt, MSD, Pfizer, Roche, and Sanofi. The R-Pharm’s facilities in the Yaroslavl and Kostroma regions implement dozens of complex advanced production technologies, which haven’t been used previously in the Russian Federation.
R-Pharm has invested in the establishment of biopharmaceutical products manufacturing facility based on FlexFactory processing line from the U.S. company Xcellerex. This facility is the first step towards the mass production of biologic drugs including innovative products and biosimilars. The plant will simultaneously be certified in the USA to meet the FDA and GMP requirements and will be the first of its kind production in Russia. Through this project the company will be able to deliver innovative medicines for the treatment of many socially significant diseases. As part of the investment agreement, Xcellerex will provide training to R-Pharm specialists in order to ensure the most rapid and effective transfer of technology and knowledge in accordance with GMP production standards and the requirements of international regulatory bodies.
R-Pharm specializes in the supply of high-tech medicinal products and laboratory equipment for the leading federal medical research centers, hospitals and clinical hospitals, as well as the largest regional curative and preventive care institutions of the Russian Federation.
The company’s portfolio includes medicinal products of various pharmaceutical groups, including oncology, hematology, cardiology, immunology, antibacterial, anti-viral, including the treatment of HIV-infection, medicinal products used in organ transplantation, treatment of disseminated sclerosis, hemophilia and diabetes, as well as neuromuscular relaxants, radiopaque contrast agents and drugs for anesthesia.
The company’s core businesses are manufacturing of finished dosage forms, active pharmaceutical ingredients of chemical nature and biotech substances; research and development of innovative products and technologies; bringing the highly efficient pharmaceutical products to the Russian market; as well as implementation of education and training programs for pharmaceutical and healthcare industries.